Abionyx Pharma SA (PA:ABNX) — Market Cap & Net Worth
Market Cap & Net Worth: Abionyx Pharma SA (ABNX)
Abionyx Pharma SA (PA:ABNX) has a market capitalization of $75.31 Million (€64.42 Million) as of September 19, 2026. Listed on the PA stock exchange, this France-based company holds position #20405 globally and #312 in its home market, demonstrating a 1.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abionyx Pharma SA's stock price €1.83 by its total outstanding shares 35279236 (35.28 Million). Also see ABNX total assets for a full breakdown of the balance sheet.
Abionyx Pharma SA Market Cap History: 2015 to 2026
Abionyx Pharma SA's market capitalization history from 2015 to 2026. Data shows change from $524.64 Million to $75.31 Million (-15.72% CAGR). Also see Abionyx Pharma SA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Abionyx Pharma SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$230.00 Billion | 0.03% | #92 of 119 |
|
CAC Small90
CACS
|
$36.76 Billion | 0.20% | #42 of 64 |
|
CAC All-Tradable
CACT
|
$2.84 Trillion | 0.00% | #152 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.84 Trillion | 0.00% | #152 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.84 Trillion | 0.00% | #152 of 179 |
|
CAC Health Care
FRHC
|
$238.85 Billion | 0.03% | #26 of 36 |
Weight: Abionyx Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abionyx Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abionyx Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Abionyx Pharma SA stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10.67x
Abionyx Pharma SA's market cap is 10.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $20.21 Million | $174.00K | -$6.30 Million | 116.15x | N/A |
| 2021 | $100.84 Million | $675.00K | -$5.82 Million | 149.40x | N/A |
| 2022 | $71.02 Million | $5.25 Million | -$4.21 Million | 13.52x | N/A |
| 2023 | $53.12 Million | $4.64 Million | -$3.52 Million | 11.45x | N/A |
| 2024 | $49.08 Million | $4.60 Million | -$4.40 Million | 10.67x | N/A |
Competitor Companies of ABNX by Market Capitalization
Companies near Abionyx Pharma SA in the global market cap rankings as of September 19, 2026. Review ABNX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Abionyx Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Abionyx Pharma SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Abionyx Pharma SA's market cap moved from $524.64 Million to $ 75.31 Million, with a yearly change of -15.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €75.31 Million | -51.76% |
| 2025 | €156.11 Million | +218.07% |
| 2024 | €49.08 Million | -7.61% |
| 2023 | €53.12 Million | -25.20% |
| 2022 | €71.02 Million | -29.57% |
| 2021 | €100.84 Million | +147.22% |
| 2020 | €40.79 Million | +193.47% |
| 2019 | €13.90 Million | -31.22% |
| 2018 | €20.21 Million | -74.35% |
| 2017 | €78.78 Million | -77.92% |
| 2016 | €356.77 Million | -32.00% |
| 2015 | €524.64 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Abionyx Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $75.31 Million USD |
| MoneyControl | $75.31 Million USD |
| MarketWatch | $75.31 Million USD |
| marketcap.company | $75.31 Million USD |
| Reuters | $75.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more